Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.46 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.45 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30334931 | 0.90 | GRM5 (0.58) | GRM5HRH3PRMT5WDR77SRD5A1 | |
| SCHEMBL24168658 | 0.90 | GRM5 (0.58) | GRM5HRH3PRMT5WDR77SRD5A1 | |
| SCHEMBL17511486 | 0.89 | GRM5 (0.57) | GRM5HRH3PRMT5WDR77SRD5A1 | |
| SCHEMBL5796029 | 0.88 | PRMT5 (0.47) | GRM5HRH3PRMT5WDR77SRD5A1 | |
| SCHEMBL1500127 | 0.85 | PRF1 (0.44) | GRM5PRMT5WDR77SRD5A1 | |
| SCHEMBL22123283 | 0.85 | KDM4E (0.47) | GRM5HRH3PRMT5WDR77SRD5A1 | |
| SCHEMBL4540354 | 0.83 | HRH3 (0.44) | GRM5HRH3PRMT5WDR77SRD5A1 | |
| SCHEMBL3654595 | 0.83 | HRH3 (0.67) | GRM5HRH3KCNH2 | |
| SCHEMBL25896981 | 0.82 | GRM5 (0.61) | GRM5HRH3PRMT5WDR77PKN2 | |
| SCHEMBL24934195 | 0.81 | PRMT5 (0.53) | GRM5HRH3PRMT5WDR77SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507521-B2 | Heterocyclic derivatives | Merck Sharp + Dohme B.V. (NL) | 2013-08-13 | — | — | US | disclosed |
| US-8507521-B2 | Heterocyclic derivatives | Merck Sharp + Dohme B.V. (NL) | 2013-08-13 | — | — | US | disclosed |
| US-8507521-B2 | Heterocyclic derivatives | Merck Sharp + Dohme B.V. (NL) | 2013-08-13 | — | — | US | disclosed |
| EP-2496569-A2 | HETEROCYCLIC DERIVATIVES | MSD Oss B.V. (NL) | 2012-09-12 | — | — | EP | disclosed |
| US-20120220622-A1 | HETEROCYCLIC DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2012-08-30 | — | — | US | disclosed |
| US-20120220622-A1 | HETEROCYCLIC DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2012-08-30 | — | — | US | disclosed |
| US-20120220622-A1 | HETEROCYCLIC DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2012-08-30 | — | — | US | disclosed |
| WO-2011051490-A2 | HETEROCYCLIC DERIVATIVES | N.V. ORGANON (NL) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220622-A1 | HETEROCYCLIC DERIVATIVES | GRIN2C, GRIN3A, GRIN2D | GRM5 5/4885HRH3 596/4885PRMT5 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.